Susquehanna International Group, LLP Heron Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 318,712 shares of HRTX stock, worth $637,424. This represents 0.0% of its overall portfolio holdings.

Number of Shares

318,712

Previous 185,898 71.44%

Holding current value

$637,424

Previous $514,000 116.93%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$2.32 - $3.86 $308,128 - $512,662	132,814 Added 71.44%	318,712 $1.12 Million
Q1 2024 May 07, 2024	BUY	$1.71 - $3.06 $199,510 - $357,019	116,673 Added 168.54%	185,898 $514,000
Q4 2023 Feb 14, 2024	SELL	$0.54 - $1.82 $61,893 - $208,602	-114,617 Reduced 62.35%	69,225 $117,000
Q3 2023 Nov 14, 2023	SELL	$0.97 - $1.8 $172,215 - $319,575	-177,542 Reduced 49.13%	183,842 $189,000
Q2 2023 Aug 11, 2023	BUY	$1.11 - $2.88 $36,306 - $94,201	32,709 Added 9.95%	361,384 $419,000
Q1 2023 May 16, 2023	SELL	$1.51 - $3.25 $10,346 - $22,269	-6,852 Reduced 2.04%	328,675 $496,000
Q4 2022 Feb 14, 2023	BUY	$2.25 - $4.67 $23,287 - $48,334	10,350 Added 3.18%	335,527 $838,000
Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $189,628 - $382,821	71,289 Added 28.08%	325,177 $1.37 Million
Q2 2022 Aug 15, 2022	SELL	$2.3 - $6.29 $328,389 - $898,073	-142,778 Reduced 35.99%	253,888 $708,000
Q1 2022 May 16, 2022	BUY	$4.63 - $9.94 $602,724 - $1.29 Million	130,178 Added 48.85%	396,666 $2.27 Million
Q4 2021 Feb 14, 2022	BUY	$8.35 - $12.6 $612,547 - $924,323	73,359 Added 37.98%	266,488 $2.43 Million
Q3 2021 Nov 15, 2021	BUY	$10.13 - $15.0 $363,758 - $538,635	35,909 Added 22.84%	193,129 $2.06 Million
Q2 2021 Aug 11, 2021	SELL	$13.27 - $18.48 $484,819 - $675,166	-36,535 Reduced 18.86%	157,220 $2.44 Million
Q1 2021 May 17, 2021	BUY	$14.49 - $20.72 $1.07 Million - $1.53 Million	73,978 Added 61.76%	193,755 $3.14 Million
Q4 2020 Feb 16, 2021	BUY	$14.61 - $22.14 $634,161 - $961,008	43,406 Added 56.84%	119,777 $2.54 Million
Q3 2020 Nov 16, 2020	SELL	$13.67 - $17.77 $959,579 - $1.25 Million	-70,196 Reduced 47.89%	76,371 $1.13 Million
Q2 2020 Aug 14, 2020	SELL	$10.89 - $21.47 $2 Million - $3.94 Million	-183,488 Reduced 55.59%	146,567 $2.16 Million
Q1 2020 May 15, 2020	BUY	$10.23 - $24.56 $2.33 Million - $5.58 Million	227,386 Added 221.47%	330,055 $3.88 Million
Q4 2019 Feb 14, 2020	SELL	$17.42 - $26.61 $1.46 Million - $2.23 Million	-83,660 Reduced 44.9%	102,669 $2.41 Million
Q3 2019 Nov 14, 2019	BUY	$16.36 - $21.39 $715,668 - $935,705	43,745 Added 30.68%	186,329 $3.45 Million
Q2 2019 Aug 16, 2019	BUY	$16.93 - $26.22 $381,957 - $591,549	22,561 Added 18.8%	142,584 $2.65 Million
Q2 2019 Aug 14, 2019	SELL	$16.93 - $26.22 $1.32 Million - $2.04 Million	-77,805 Reduced 39.33%	120,023 $2.23 Million
Q1 2019 May 15, 2019	BUY	$23.15 - $28.34 $3.84 Million - $4.7 Million	165,921 Added 520.01%	197,828 $4.84 Million
Q4 2018 Feb 14, 2019	SELL	$22.03 - $32.01 $43,839 - $63,699	-1,990 Reduced 5.87%	31,907 $828,000
Q3 2018 Nov 14, 2018	SELL	$30.0 - $40.85 $2.17 Million - $2.96 Million	-72,439 Reduced 68.12%	33,897 $1.07 Million
Q2 2018 Aug 14, 2018	BUY	$26.4 - $42.0 $1.62 Million - $2.58 Million	61,511 Added 137.22%	106,336 $4.13 Million
Q1 2018 May 15, 2018	SELL	$18.43 - $28.8 $3.95 Million - $6.18 Million	-214,557 Reduced 82.72%	44,825 $1.24 Million
Q4 2017 Feb 14, 2018	SELL	$14.8 - $18.85 $1.12 Million - $1.42 Million	-75,545 Reduced 22.56%	259,382 $4.7 Million
Q3 2017 Nov 14, 2017	BUY	$14.65 - $16.85 $4.91 Million - $5.64 Million	334,927	334,927 $5.41 Million

Others Institutions Holding HRTX

# of Institutions

198

Shares Held

129M

Call Options Held

94.7K

Put Options Held

148K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $238M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Heron Therapeutics, Inc. Transaction History